ARYLAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND

PROBLEM TO BE SOLVED: To provide a compound useful as an inhibitor of a kinase activity of EML4-ALK fusion protein.SOLUTION: The present inventors conducted intensive studies about a compound having an inhibitory activity of the kinase activity of EML4-ALK fusion protein and found that the arylamino...

Full description

Saved in:
Bibliographic Details
Main Authors ASAUMI MAKOTO, NISHIMURA KOICHI, MATSUYA TAKAHIRO, SHINTO NOBUAKI, SHIMADA ITSURO, FUTAMI TAKASHI, KAWASE TATSUYA, KAMIKAWA AKIO, IWAI TATSUNORI, TOMIYAMA YASUSHI, SANO YORIMASA, YAMANAKA AYA, KUROSAWA KAZUO, IIKUBO KAZUHIKO, KUROMITSU SADAO
Format Patent
LanguageEnglish
Published 16.01.2014
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:PROBLEM TO BE SOLVED: To provide a compound useful as an inhibitor of a kinase activity of EML4-ALK fusion protein.SOLUTION: The present inventors conducted intensive studies about a compound having an inhibitory activity of the kinase activity of EML4-ALK fusion protein and found that the arylamino heterocyclic carboxamide compound of the present invention has the inhibitory activity of the kinase activity of EML4-ALK fusion protein, and completed the present invention. The compound of the present invention may be used for a pharmaceutical composition for preventing and/or treating cancer, lung cancer, non-small cell lung cancer, small cell lung cancer and the like.
Bibliography:Application Number: JP20100236958